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Platelet-Activating Factor Acetylhydrolase (PAFAH) is a monocyte-derived 
phospholipase A2 that catalyzes the hydrolysis of platelet-activating factor (PAF) and has 
been implicated in atherosclerosis. Although PAF and other proinflammatory stimuli are 
postulated to induce the enzyme, mechanisms controlling PAFAH expression are largely 
unknown at present. We have shown that PAFAH induction in monocytes is increased in 
response to oxidized phospholipids. The PAFAH 5’ flanking region has at least 10 putative 
Stat elements, and IL-6 has been shown to be downstream from the prostaglandin receptor, 
EP2, which has been shown to bind oxidized phospholipids, prompting the hypothesis that 
v 
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Stat proteins might regulate its expression. To test this hypothesis, we treated human 
monocytes with IL-6, a monocyte-derived cytokine that activates Stat3, IL-8, a monocyte-
derived cytokine induced by Stat3, and oxidized 1-palmitoyl-2-arachidonoyl-sn-3-
phosphocholine (oxPAPC), a major component of the oxidized LDL particle. Two 
monocyte-derived cell types, macrophages (MO) and dendritic cells (DC) were prepared 
from primary human monocytes. The cells were treated with various doses of IL-6, IL-8, 
or oxPAPC for various time frames in the absence of serum. Culture supernatants from the 
cytokine-treated cells were harvested and screened for PAFAH protein and activity and 
cell monolayers were assessed for PAFAH mRNA by quantitative real time PCR (qPCR). 
Cells treated with oxPAPC were further analyzed for secreted IL-6 using ELISA and 
activation of Stat3 using Western Blot. Both IL-6 and IL-8 induced PAFAH expression in 
a dose-dependent manner. Although both MO and DC responded to the cytokines, 
preliminary experiments suggested that induction of PAFAH is more robust in DC than 
MO. Cytokine-treated cells exhibited increased PAFAH activity in their culture 
supernatants that correlated with increased PAFAH protein levels. Treatment with 
oxPAPC induced IL-6 secretion and subsequent Stat3 activation in DC. Together, these 
data support the hypothesis that PAFAH expression is regulated by oxidized phospholipids 
and proinflammatory cytokines in developing atheromas. 
 
 
 
 
 
 
Introduction 
 
Atherosclerosis is a chronic inflammatory condition affecting arterial blood vessels. 
The chronic inflammatory response is due to the buildup of low-density lipoprotein (LDL) 
in the arterial intima, where it can be oxidized by a variety of different cellular processes or 
free radicals. In response, white blood cells then migrate into the arterial wall. They begin 
to adhere to the walls of the artery and develop into large fatty foam cells. As these cells 
continue to accumulate, a fatty streak is formed. Eventually, necrosis and subsequent 
fibrosis may occur in the streak, causing development of a plaque, which may finally 
rupture and cause formation of an occlusive blood clot (Fig 1). 
The buildup of LDL in the arterial intima and its subsequent oxidation serves as a 
chemo-attractant for monocytes, which is what causes these cells to migrate into the 
arterial intima. There, they may differentiate into other monocyte-derived cell types such 
as dendritic cells or macrophages. Through the action of their scavenger receptors, they 
uptake large amounts of oxidized LDL and develop into large foam cells, which adhere to 
the walls of the artery and contribute to the developing atheroma (Fig 2) (1). 
1 
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Figure 1: The development of an atherosclerotic plaque in the wall of artery. Lodish et al, 
2004, p. 768. 
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Figure 2: Migration and differentiation of monocytes in the arterial intima and large foam 
cell formation. Lodish et al, 2004, 769. 
4 
The LDL particle can become trapped and build up in the arterial intima and then 
become oxidized (2). The core of the LDL particle is comprised of triglycerides, 
cholesteryl esters, and free cholesterol. However, the surface of the LDL particle is 
dominated by oxidized phospholipids. It is these oxidized phospholipids that are some of 
the agents responsible for signaling in atherosclerosis (3). OxPAPC (oxidized 1-palmitoyl-
2-arachidonoyl-sn-3-phosphocholine) is a major component of the oxidized LDL particle. 
Upon oxidation, other modified phosphatidylcholines become present that have oxidatively 
fragmented or modified sn-2 acyl chains. Among the major components of oxPAPC are 1-
palmitoyl-2-(5-oxovaleroyl)-sn-3-phosphocholine (POVPC), 1-palmitoyl-2-(5,6-
epoxyisoprostane E2)-sn-3-phosphocholine (PEIPC), and 1-palmitoyl-2-glutaroyl-sn-3-
phosphocholine (PGPC) (4). It has been shown that the long chain fractions, such as 
PEIPC, as opposed to the short chain fractions, such as PGPC and POVPC, are the 
bioactive lipids that cause signaling in developing atheromas (5). In addition, the moiety 
present on the sn-2 position of PEIPC bares a similar structure to that of a prostaglandin. 
Theoretically, this may play a role in its ability to bind receptors involved in developing 
atheromas. 
In addition to acting as a chemo-attractant and inducing the recruitment of 
monocytes to the arterial intima, oxidized phospholipids have been shown to induce 
secretion of proinflammatory cytokines that exacerbate atherosclerosis. In particular, 
studies have shown that plasma concentrations of Interleukin-6 (IL-6) and Interleukin-8 
(IL-8) are elevated in patients with atherosclerosis (6;7). 
5 
The enzyme Platelet-Activating Factor Acetylhydrolase (PAFAH) has also been 
shown to be upregulated in atherosclerosis. PAFAH is a secreted, 45kDa, calcium-
independent phospholipase A2 that catalyzes the hydrolysis of platelet activating factor 
(PAF) and other short-chain or oxidatively fragmented phospholipids at the sn-2 position 
(Fig 3). PAFAH can associate with lipoproteins and is also referred to as the lipoprotein-
associated phospholipase A2. In general, phospholipase A2 is known to be an upstream 
regulator of inflammatory responses. Upon cleaving phospholipids at the sn-2 position, 
arachidonic acid and lysophospholipids are released, which can then be modified into 
various inflammatory mediators, such as prostaglandins or leukotrienes. PAFAH differs 
from other types of phospholipase A2 in that it is calcium independent and secreted (8). 
Monocytes are the major source of secreted PAFAH in the circulation, and it has 
been shown that expression of PAFAH increases greatly when monocytes differentiate into 
macrophages, and to a lesser extent, dendritic cells (9;10). 
PAFAH is implicated in atherosclerosis, and its presence correlates with the 
severity of the disease. However, its role is controversial with some studies suggesting 
protection but others indicating that the enzyme exacerbates disease. One study showed 
that Japanese subjects with a mutation nullifying PAFAH activity had a higher rate of heart 
attack and atherosclerosis. However, another study showed that in European men, the same 
loss of function mutation correlated with a reduced risk of heart attack or coronary artery 
disease (10-15). While it is clear that PAFAH plays a role in atherosclerosis, few studies 
have addressed the regulation of its expression and activity in atherosclerotic lesions. 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Mechanism of PAFAH activity. PAFAH selectively hydrolizes PAF and other 
short-chain phospholipids at the sn-2 position, catabolizing them, but also releasing 
bioactive lipids. 
7 
It has previously been shown that oxidized 1-palmitoyl-2-arachidonoyl-sn-3-
phosphocholine (oxPAPC), a major component of oxidized LDL, can bind the 
prostaglandin EP2 receptor (3;5;16;17). Our lab has also shown that PAFAH induction is 
increased in response to oxPAPC in dendritic cells, but not macrophages (Fig 4). 
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Figure 4: Differential response in dendritic cells and macrophages. PAFAH induction is 
increased in response to oxPAPC in a.) dendritic cells, but not b.) macrophages. 
9 
It has previously been shown that lipopolysaccharide (LPS) strongly induces 
PAFAH expression. LPS is a classical stimulus of inflammation, suggesting that the 
upregulation of PAFAH is also mediated similarly. In addition, the transcription factors, 
Sp1 and Sp3 are required for both LPS-induced expression as well as basal expression. Sp1 
and Sp3 bind to a GC-rich box in the 5’ flanking region of the PAFAH gene, however the 
relative levels of Sp1 and Sp3 are not increased during LPS-stimulated PAFAH induction, 
suggesting another factor may be involved (18-20). In the 5’ flanking region, there also 
exists an interferon-gamma activated sequence (GAS), a classic target of Stat transcription 
factors. Because EP2 has been previously shown to be involved in oxPAPC signaling, and 
that IL-6 is downstream of EP2 (21;22), IL-6 activation of Stat3 and its subsequent 
activation of PAFAH could be a novel mechanism illustrating the induction of PAFAH by 
oxidized phospholipids in atherosclerosis. 
In addition, it has been shown in endothelial cells that IL-8 induction is increased in 
response to oxidized phospholipids in a Stat3 dependant mechanism (22). This suggests 
that IL-8 could also be involved in the induction of PAFAH by oxidized phospholipids and 
proinflammatory cytokines. 
10 
 
 
 
 
 
 
 
 
GAS GC-Box
-340 - -332 -80 — -75
+1
Potential –Regulatory Region (-1308 – -294)Potential –Regulatory Region(-3416– -1308)
 
 
 
 
Figure 5: The PAFAH 5’ Flanking Region has a GC box and a GAS sequence. Sp1 and 
Sp3 are required for basal expression, and bind the GC box. The GAS sequence is a classic 
target for Stat3 binding, thus driving PAFAH expression. 
  
Hypothesis 
 
We hypothesize that in atherosclerosis, oxPAPC induces dendritic cells to express 
increased levels of PAFAH by binding the EP2 receptor. This causes an increase in IL-6 
secretion which autocrinely activates the cell of origin or paracrinely activates adjacent 
dendritic cells. IL-6 then activates Stat3, which drives PAFAH expression and secretion. 
Subsequently, Stat3 drives IL-8 expression which then augments the PAFAH response 
through an unknown mechanism. 
11 
  
Methods 
 
Isolation of Monocytes and Differentiation into Dendritic Cells and Macrophages: 
Peripheral blood leukocytes were extracted from human blood using lymphocyte 
separation media (LSM). The  cells were treated with cytokines to induce differentiation; 
1000 U/mL M-CSF in 10% human serum in RPMI for Macrophages, 800 U/mL GM-CSF 
and 500 U/mL IL-4 in 10% fetal calf serum in RPMI for Dendritic Cells. 
Cytokine Activation: After 1 week of differentiation, macrophages and dendritic cells were 
treated with various concentrations (.1ng/mL, 1ng/mL, 10ng/mL) of IL-6 or IL-8 in serum-
free RPMI, or 10ug/mL oxPAPC in 0.5% fatty-acid free BSA/serum free RPMI. Various 
time points were used, and post-treatment, cells and culture supernatants were harvested. 
 
PAFAH Activity Assay: Substrate for PAFAH activity assay was 50mM 1-alkyl-2-acetyl-
sn-glycero-3-phosphocholine (PAF) with .05µCi hexadecyl-2-acetyl-sn-glyceryl-3-
phosphocholine, 1-O-[acetyl-(N)-3H] (13.5Ci/mmol) Substrate was incubated with culture 
supernatant for 30 min at 37°C. PAFAH activity was determined by the release of 
3H-acetate and quantified via scintillation counting as described previously (4). 
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Western Blot: Equal quantities of protein from culture supernatants were precipitated in 
PBS and trichloroacetic acid at a final concentration of 20% for 30 minutes on ice. 
Samples were centrifuged and supernatants were discarded. Samples were washed with 
300µL of acetone, dried under air, and then resuspended in SDS-PAGE sample buffer. 
PAFAH protein was detected with a rabbit antibody against the human enzyme (Cayman) 
and HRP-coupled anti-rabbit (Pierce). Protein from whole cell homogenates was collected 
in RIPA buffer and analyzed for Stat3 and phospho-Stat3 with mouse antibodies and HRP-
coupled anti-mouse (Cell Signaling). 
 
Isolation of RNA and qPCR Analysis: RNA was harvested from cells using Trizol reagent 
(Invitrogen) and analyzed for PAFAH transcripts via Real Time PCR (qPCR) using 
PAFAH specific primers, 18S specific primers, and TaqMan One-Step kit from ABI on an 
ICycler instrument from BioRad, as described previously (4). 
 
ELISA Analysis: Culture supernatant was harvested from cells and ELISA analysis (BD 
OptEIA IL6 ELISA kit from BD Bioscience) was performed by Megan Price with our 
thanks. 
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Flow Cytometry Analysis: FcR blocking reagent (Miltenyi Biotec) was incubated with 105 
cells for 10 minutes. Cells were incubated with PE-labeled IL-6R antibody or isotype 
matched control (BD Pharmingen) for 30 minutes before thorough washing in PBS. 
Stained cells were analyzed using a FACScan (Becton Dickinson) and data were analyzed 
using WinMDI. Data obtained and magnanimously shared by Rachael Griffiths. 
 
Statistical Analysis: Data are shown from a single representative experiment done in 
triplicate, and experiments are n >= 3 unless otherwise noted. Statistical significance 
determined using the student’s t-test, p < 0.05. 
Results 
 
 IL-6 Induces PAFAH Secretion and Activity in Dendritic Cells: We hypothesized 
that IL-6 mediates the elevation of PAFAH expression in response to oxidized 
phospholipids. To test one element of this hypothesis, we first treated monocytes with 
exogenous IL-6 to see if IL-6 does indeed induce PAFAH.  Dendritic cells were treated 
with .1ng/mL, 1ng/mL, or 10ng/mL IL-6 in serum-free media for 16 hours. The 
supernatant was harvested and analyzed for PAFAH activity using a radiometric enzymatic 
activity assay and scintillation counting. Supernatant was also TCA precipitated and 
PAFAH protein was analyzed using a Western Blot. There is a dose-dependant increase in 
both PAFAH activity and protein in response to IL-6 treatment (Fig 6). 
15 
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a.) 
 
 
 
b.)       
                              Control        .1ng/mL IL-6  1ng/mL IL-6  10ng/mL IL-6 
 
 
 
Figure 6: IL-6 Induces PAFAH in Dendritic Cells. a.) Specific Activity of PAFAH 
enzyme, and b.) PAFAH protein from culture supernatants. Representative replicate 
experiment performed in triplicate, n = 3, p < .05. 
17 
IL-6 Induces PAFAH in Dendritic Cells, but not Macrophages: To see if 
macrophages behave the same as dendritic cells in response to IL-6, we treated both 
dendritic cells and macrophages with IL-6 and compared their response. Dendritic cells 
and macrophages were treated with .1ng/mL, 1ng/mL, or 10ng/mL IL-6 in serum-free 
media for 16 hours. The supernatant was harvested and analyzed for PAFAH activity using 
a radiometric enzymatic activity assay and scintillation counting. PAFAH is strongly 
induced in dendritic cells, but the induction of PAFAH in macrophages, while sometimes 
significant, is weak and not reproducible (Fig 7). 
18 
 
 
 
 
 
 
 
 
Figure 7: IL-6 Induces PAFAH Activity in Dendritic Cells, but not in 
Macrophages. Representative replicate experiment performed in triplicate, n = 3, p 
< .05. 
19 
IL-8 Induces PAFAH Secretion and Activity in Dendritic Cells: We hypothesized 
that IL-8 was involved in the induction of PAFAH by oxidized phospholipids. To test this, 
we treated dendritic cells with exogenous IL-8 to see if it induces PAFAH. Dendritic cells 
were treated with .1ng/mL, 1ng/mL, or 10ng/mL IL-8 in serum-free media for 16 hours. 
The supernatant was harvested and analyzed for PAFAH activity using a radiometric 
enzymatic activity assay and scintillation counting. Supernatant was also TCA precipitated 
and PAFAH protein was analyzed using a Western Blot. There is a dose-dependant 
increase in both PAFAH activity and protein in response to IL-8 treatment (Fig 8). 
20 
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b.) 
                                        Control     .1ng/mL IL-8  1ng/mL IL-8   10ng/mL IL-8 
 
 
 
 
 
 
 
Figure 8: IL-8 Induces PAFAH in Dendritic Cells. a.) Specific Activity of PAFAH 
enzyme, and b.) PAFAH protein from culture supernatants. Representative replicate 
experiment performed in triplicate, n = 3, p < .05. 
21 
IL-8 Induces PAFAH in Dendritic Cells, but not Macrophages: To see if 
macrophages behave the same as dendritic cells in response to IL-8, we treated both 
dendritic cells and macrophages with IL-8 and compared their response. Dendritic cells 
and macrophages were treated with .1ng/mL, 1ng/mL, or 10ng/mL IL-8 in serum-free 
media for 16 hours. The supernatant was harvested and analyzed for PAFAH activity using 
a radiometric enzymatic assay and scintillation counting. Similar to the IL-6 trials, PAFAH 
is strongly induced in dendritic cells, but the induction of PAFAH in macrophages, while 
significant, is either weak or not reproducible (Fig 9). 
22 
 
 
 
 
 
 
 
 
 
Figure 9: IL-8 Induces PAFAH Activity in Dendritic Cells, but not in 
Macrophages. Representative replicate experiment performed in triplicate, n = 3, p 
< .05. 
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IL-6 Receptor is More Highly Expressed in Dendritic Cells than in Macrophages: 
We hypothesized that IL-6 is a key mediator of the induction of PAFAH in response to 
oxidized phospholipids. We found that IL-6 induces PAFAH in dendritic cells, but the 
response in macrophages is either blunted or absent. To test if the IL-6 receptor plays a 
role in this differential response, we used flow cytometry analysis to examine the cell 
surface expression of the IL-6 receptor in both cell types. Dendritic cells and macrophages 
were incubated with a Fc receptor blocking reagent, and then incubated with a PE-labeled 
IL-6 receptor antibody or an isotype matched control. While only a small amount of IL-6 
receptor cell surface expression was detectable in macrophages, a significant increase was 
observed in the IL-6 receptor cell surface expression in dendritic cells (Fig 10). High 
expression of the IL-6 receptor in dendritic cells compared to macrophages is one possible 
explanation for why dendritic cells respond to IL-6 and macrophages do not. 
24 
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Figure 10: The IL-6 Receptor is more highly expressed in dendritic cells than in 
macrophages, shown by examining the cell surface expression using flow cytometry 
analysis. Cell surface expression of IL-6R in a.) macrophages and b.) dendritic cells. The 
open gray trace is a blank, negative control, and overshadowing it is the black trace, which 
is a negative isotype match control. The colored traces are specific for the IL-6 receptor. 
25 
Induction of PAFAH by oxPAPC is not Immediate: In our hypothesis, we suggest 
that IL-6 mediates the induction of PAFAH by oxidized phospholipids in an autocrine or 
paracrine fashion. Some time would be required for any upstream cell signaling events to 
take place before PAFAH induction, so we performed time-course studies with dendritic 
cells treated with oxPAPC and observed when PAFAH activity and expression become 
elevated. Dendritic cells were treated with 10ug/mL oxPAPC in 0.5% fatty-acid free 
bovine serum albumin (BSA) in serum-free media or treated with vehicle, 0.5% fatty-acid 
free BSA. The supernatant was harvested and analyzed for PAFAH activity using a 
radiometric enzymatic activity assay and scintillation counting. Cells were harvested in 
Trizol reagent and RNA was isolated and quantified with real time quantitative PCR. 
There is a lag phase between initial oxPAPC treatment and the appearance of PAFAH 
expression and activity in the treated cells compared to cells treated with vehicle. PAFAH 
expression is elevated at 8 hours and activity begins to appear approximately 8-16 hours 
post-treatment. Early time points are also noteworthy, due to modest suppression of both 
PAFAH activity and expression. This suppression is not an artefact, as it is reproducible. 
(Fig 11). 
26 
a.) 
 
b.) 
 
Figure 11: OxPAPC-induced PAFAH Expression and Activity follow a lag phase. 
Dendritic cells were treated with oxPAPC or vehicle, and PAFAH a.) activity and b.) 
expression were analyzed at various time points, represented here fold-to-vehicle. 
Representative replicate experiment performed in triplicate, n = 3, p < .05. 
27 
Ox-PAPC Induces Secretion of IL-6 in Dendritic Cells: We hypothesized that IL-6 
mediates the induction of PAFAH by oxidized phospholipids in dendritic cells in an 
autocrine fashion. To test this element of our hypothesis, we treated dendritic cells with 
oxPAPC and used ELISA to observe the secretion of IL-6. Dendritic cells were treated 
with 10ug/mL oxPAPC in 0.5% fatty-acid free BSA in serum-free media or vehicle. The 
supernatant was harvested and analyzed for secreted IL-6 using ELISA. At 4 hours, 
induction of IL-6 in the oxPAPC treated cells is increased compared to the vehicle treated 
cells. Interestingly, suppression of IL-6 secretion is observed at early time points, similar 
to PAFAH activity and expression (Fig 12). 
28 
 
 
 
 
 
Figure 12: OxPAPC-induces secretion of IL-6 in Dendritic Cells. Dendritic cells were 
treated with oxPAPC or vehicle and culture supernatant was analyzed at various time 
points for the presence of secreted IL-6 using ELISA, represented here fold to control. 
n = 1, p < .05. 
29 
OxPAPC Treatment Activates Stat3 in Dendritic Cells: We hypothesized that IL-6 
mediates the induction of PAFAH by oxidized phospholipids. Stat3 is a classic target of 
IL-6, thus we used Western Blot analysis to observe the activation of Stat3 in dendritic 
cells in response to treatment with oxPAPC. Dendritic cells were treated with 10ug/mL 
oxPAPC in 0.5% fatty-acid free BSA in serum-free media or vehicle. At various time 
points, whole cell homogenates were harvested in RIPA buffer. The activated form of 
Stat3, tyrosine phosphorylated Stat3, was analyzed by Western Blot analysis. At 4 hours, 
the presence of phospho-Stat3 in the oxPAPC treated cells is increased compared to the 
vehicle treated cells (Fig 13). 
30 
 
 
 
 
 
 
 
 
Figure 13: OxPAPC treatment activates Stat3 in Dendritic Cells. Dendritic cells 
were treated with oxPAPC or vehicle and whole cell homogenates were collected at 
various time points in RIPA buffer and analyzed for phospho-Stat3 and total Stat3. 
n = 1. 
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IL-6 Induction of PAFAH Activity is Present by 8 hours: We hypothesized that IL-6 
mediates the elevation of PAFAH expression in response to oxidized phospholipids. To 
determine when this elevation occurred, we treated dendritic cells with exogenous IL-6.  
Dendritic cells were treated with 10ng/mL IL-6 in serum-free media and culture 
supernatant was harvested at various time points. The supernatant was then analyzed for 
PAFAH activity using a radiometric enzymatic activity assay and scintillation counting. 
PAFAH enzymatic activity was observed to be elevated by approximately 8 hours post   
IL-6 treatment (Fig 14). 
32 
 
 
 
 
 
 
 
 
Figure 14: IL-6 Induces PAFAH Activity in Dendritic Cells by 8 hours. Specific 
Activity of PAFAH enzyme was quantified from culture supernatants. 
Representative replicate experiment, n = 2, p < .05. 
 
 
 
 
 
Discussion 
 
 We hypothesized that in atherosclerosis, oxPAPC induces dendritic cells to express 
increased levels of PAFAH by binding the EP2 receptor. This causes an increase in IL-6 
secretion which autocrinely activates the cell of origin or paracrinely activates adjacent 
cells. IL-6 then activates Stat3, which drives PAFAH expression and secretion. 
Subsequently, Stat3 drives IL-8 expression which then augments the PAFAH response 
through an unknown mechanism. 
 Here, we have shown that IL-6 and IL-8 robustly induce PAFAH expression and 
activity in dendritic cells but not in macrophages. We have shown that this differential 
response may in part be due to the decreased expression of cell surface IL-6 receptor in 
macrophages. We have conducted time-course studies of oxPAPC-induced activation of 
PAFAH in dendritic cells, showing that PAFAH expression is elevated 8 hours post-
treatment and that PAFAH activity begins to rise approximately 8-16 hours post-treatment, 
demonstrating that a lag phase precedes activation, suggesting other cellular signaling 
pathways are required to be activated first. We have shown that IL-6 is being secreted from 
dendritic cells activated with oxPAPC, and that this increase in IL-6 is most apparent at 4 
hours. We have also shown that Stat3 is being activated in dendritic cells treated with 
oxPAPC, also at 4 hours post-treatment. 
These time course data support our model, illustrating that IL-6 and Stat3 are being 
activated approximately 4 hours post-treatment with oxPAPC, followed by an increase in 
PAFAH expression at 8 hours, and finally an increase in PAFAH activity between 8 and 
33 
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16 hours (Fig 15). The IL-6 time course data also adhere to this model. IL-6-induced 
PAFAH activity was not apparent until 8 hours post-treatment, suggesting that if IL-6 
secretion is at its highest around 4 hours post-oxPAPC treatment, then perhaps 8 hours 
after the secretion of IL-6, PAFAH activity increases. This fits into our time course data of 
PAFAH activity being elevated between 8 and 16 hours post-oxPAPC treatment. 
35 
 
 
 
 
 
 
Figure 15: Time-course showing changes in IL-6 secretion, Stat3 activation, and PAFAH 
expression and activity. IL-6 secretion increases at 4 hours, Stat3 is then phosphorylated, 
followed by an increase in PAFAH expression, and finally PAFAH activity. Previous IL-6 
treatment time-course experiments have shown an increase in PAFAH activity after 8 
hours, supporting this data. 
36 
 
 
 
 
 
 
 
 
 
 
Figure 16: Theoretic Model. We hypothesize that oxidized phospholipids induce PAFAH 
by binding the EP2 receptor. This interaction induces IL-6 which further activates dendritic 
cells in an autocrine fashon. IL-6 activates STAT-3, a transcription factor that 
not only induces PAFAH, but also induces IL-8 which further augments PAFAH 
induction by binding its receptor. 
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While our evidence heavily supports our model, further studies must be conducted 
to determine whether IL-6 is actually the mediating factor by which oxPAPC activates 
PAFAH in dendritic cells. We have shown that IL-6 secretion is not only upregulated in 
response to oxPAPC, but that IL-6 induces PAFAH activity. To confirm that IL-6 is the 
link between oxPAPC and PAFAH induction, blocking IL-6 in oxPAPC treated cells and 
abolishing the induction of PAFAH would neatly illustrate our model. While siRNA is not 
a favorable option due to the difficulty with transfection in primary monocytes, a 
neutralizing antibody against IL-6 or the IL-6 receptor should be more feasible. 
Furthermore, other studies to confirm our model must be conducted. As we have shown 
the increase in secretion of IL-6 from dendritic cells and the increase of the IL-6 receptor 
on the cell surface of dendritic cells compared to macrophages, we must also study the 
secretion of IL-8 and the cell surface expression of the IL-8 receptor. We are also currently 
performing quantitative real time PCR for IL-6 and IL-8 transcripts to quantify any 
upregulation on the expression level. Furthermore, more time-course studies must be 
conducted to determine when IL-8 is becoming upregulated in response to oxPAPC and 
when that has an effect on PAFAH upregulation. If our hypothesis regarding IL-8 is 
correct, secretion of IL-8 would be detectable further down the pathway, between 16-24 
hours. While it is not surprising that PAFAH enzymatic activity is still elevated at 24 
hours, it is interesting that PAFAH expression is still elevated at 24 hours despite any 
cellular degradation and turnover of mRNA, suggesting that perhaps this is an effect of IL-
8 further augmenting the induction of PAFAH. 
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In addition, more studies must be conducted to explain the early suppression of 
PAFAH activity, PAFAH expression, and IL-6 secretion. Our lab has shown that PAF and 
other short-chain PAF-like lipids can suppress PAFAH induction. One possibility may be 
that oxidatively-fragmented short-chain lipids present in oxPAPC are signaling through the 
PAF receptor or an unidentified receptor. To determine if this is true, a time course study 
would need to be conducted in which we treat dendritic cells with a PEIPC-rich fraction 
and see if the early suppression is abolished or remains. 
In conclusion, our data supports our model that PAFAH levels are induced by 
proinflammatory mediators that have already been associated with the progression of 
atherosclerotic lesions, and that a clinical treatment may be developed by further 
elucidating the mechanism of PAFAH regulation. 
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